Chest
Pulmonary and Cardiovascular: CHEST ReviewsThe Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment
Section snippets
How Is PH-ILD Defined, and How Often Does It Occur?
The 6th WSPH recently updated the definition of group 3 PH to a resting mean pulmonary artery pressure (mPAP) > 20 mm Hg, with an accompanying pulmonary vascular resistance (PVR) ≥ 3 Wood units and a pulmonary artery occlusion pressure (PAOP) ≤ 15 mm Hg at right-sided heart catheterization (RHC) in the setting of chronic lung disease (Table 1).5 Severe group 3 PH is defined as an mPAP ≥ 35 mm Hg or mPAP ≥ 25 mm Hg with a cardiac index of < 2.0 L/min/m2 and PAOP ≤ 15 mm Hg.5 The distinction
What Are the Effects of PH-ILD?
The development of PH-ILD is associated with substantial morbidity in the form of increased need for supplemental oxygen, increased symptoms of dyspnea, and reduced mobility. The effect has been examined in two ways: (1) comparison with ILD without PH and (2) comparison with other PH causes. Lettieri and colleagues9 found patients with PH-IPF had a lower mean 6-min walk test (6MWT) distance (143.5 m ± 65.5 vs 365.9 m ± 81.8; P < .001) and lower oxygen desaturation nadir (80.1% ± 3.7
What Causes PH-ILD to Occur?
The pathogenesis of PH-ILD is incompletely understood, but it appears a number of factors are at play. Hypoxic pulmonary vasoconstriction (HPVC) may occur in response to alveolar hypoxemia, pulmonary arterial hypoxemia, hypercapnia, or acidemia. Although HPVC is typically reversible with supplemental oxygen, repeated or sustained episodes may result in pulmonary vascular remodeling and PAH.22 In addition, chronic hypoxia appears to interfere with the ability of endothelial nitric oxide synthase
Who Should Be Evaluated for PH-ILD, and How Should It Be Diagnosed?
No standard exists regarding which patients to screen for PH-ILD or the optimal method of doing so. The diagnosis can be difficult to make as there is significant overlap of symptoms between fibrotic lung disease and PH.27 The physical examination also lacks the sensitivity to predict PH-ILD accurately. A recent study showed no individual physical examination finding could accurately predict PH.28 The combination of jugular venous distension, peripheral edema, and a parasternal heave was
What Is the Rationale Behind Treatment of PH-ILD?
Given the morbidity and mortality associated with PH-ILD and current absence of available treatments, as well as the large armamentarium of pulmonary vasodilators that have been successfully used in PAH, it is not surprising that there has been great interest in the treatment of PH-ILD with pulmonary vasodilator therapy. Arguments both for and against treatment have been made. One potentially negative effect of pulmonary vasodilator therapy is worsening hypoxemia due to uncoupling of the
What Have the Studies on PH-ILD Performed So Far Shown?
Multiple clinical trials of pulmonary vasodilator therapy in ILD have been performed, mostly with disappointing results. Although a mounting number of studies have been performed in PH-ILD, there remain major deficiencies in the available literature. The biggest flaw is that most trials enrolled patients with PH diagnosed on the basis of diffusion capacity and/or TTE criteria rather than hemodynamically. Moreover, no trial has focused specifically on severe PH-ILD. Such a trial is difficult to
The End of Endothelin Receptor Antagonists?
Six randomized controlled trials (RCTs) have examined the role of endothelin receptor antagonists (ERAs) in IPF. Four of these trials aimed to evaluate the effects of ERAs on functional status and parenchymal disease progression in patients with ILD rather than in those with PH-ILD. RCTs of bosentan and macitentan both failed to demonstrate improvements in slowing disease progression and did not appear to have salutary effects on functional status.49, 50, 51 The Randomized, Placebo-Controlled
Say NO to Drugs: The RISE and Fall of Riociguat
A pilot trial of the soluble guanylate stimulator riociguat in PH-ILD generated enthusiasm after demonstrating improvements in hemodynamics with few safety events.55 This study served as the impetus for the Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (RISE-IIP) study, a phase IIb study of riociguat in patients with idiopathic interstitial pneumonias with RHC-confirmed PH.56 The study was terminated early
Phosphodiesterase 5 Inhibitors: Sildenafil Saga
The results of the clinical trials and registry data examining the role of sildenafil in PH-ILD are the most promising to date. The COMPERA registry enrolled incident patients with PH-ILD who had pulmonary vasodilator therapy initiated. The majority (88%) of the 151 patients followed up were treated with phosphodiesterase 5 inhibitors. The treated group demonstrated a median improvement in 6MWT distance of 24.5 m and nearly one-quarter improved functional class.11 Moreover, patients whose 6MWT
Prostanoids to the Rescue?
Until recently, data on the safety and efficacy of prostanoids in PH-ILD were limited to several small series. Olschewski and colleagues45 studied the effects of both IV and inhaled prostanoids in eight patients with PH-ILD. They found IV therapy decreased systemic BP and arterial oxygen saturation, but inhaled therapy was well tolerated. Ghofrani and colleagues44 conducted a small RCT comparing IV epoprostenol (n = 8) and oral sildenafil (n = 8); they found epoprostenol worsened oxygenation
Should PH-ILD Be Treated? If So, How?
There is no universally agreed on approach to the treatment of PH-ILD. Patients with PH-ILD have a poor prognosis and should be evaluated and listed for LTx when appropriate. However, we emphasize that use of pulmonary vasodilator therapy in patients with ILD should be undertaken only by experienced PH centers. We hope that clinical trials focused on severe group 3 PH will emerge, and, whenever available, we strongly advocate for populating these studies to enrich the existing body of
What Is the Future of PH-ILD?
The INCREASE trial is a major step forward in the treatment of PH-ILD. We hope its results will stimulate further research in the area. A randomized, double-blind, placebo-controlled clinical study to assess the safety and efficacy of pulsed, inhaled nitric oxide (iNO) in subjects with pulmonary hypertension associated with pulmonary fiborsis on long term oxygen therapy (PULSE), a clinical trial of inhaled nitric oxide in PH-ILD, has demonstrated favorable patient-reported outcomes and
Conclusions
PH-ILD is an incompletely understood clinical entity, which complicates the clinical course of many patients with ILD. It is recognized to be associated with significant morbidity and mortality. Effective therapeutic strategies are currently lacking; however, clinical trials to address this gap in the medical literature are currently underway.
Acknowledgments
Financial/nonfinancial disclosures: The authors have reported to CHEST the following: C. S. K. is a speaker for Boehringer Ingelheim; Genentech, Inc; and Johnson & Johnson and has done consulting for Boehringer Ingelheim, Johnson & Johnson, and United Therapeutics, as well as for the France Foundation. O. A. S. has done consulting and is a speaker for Bayer AG, Johnson & Johnson, and United Therapeutics.
References (78)
- et al.
A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation
J Heart Lung Transplant
(2015) - et al.
Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis
Chest
(2006) - et al.
Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis
Respir Med
(2009) - et al.
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Chest
(2005) - et al.
The Giessen Pulmonary Hypertension Registry: survival in pulmonary hypertension subgroups
J Heart Lung Transplant
(2017) - et al.
Significance of PAP and diffusion capacity of the lung as prognosticator in patients with IPF
Chest
(2007) Group III pulmonary hypertension: pulmonary hypertension associated with lung disease—epidemiology, pathophysiology, and treatments
Cardiol Clin
(2016)- et al.
Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis
Chest
(2007) - et al.
A prospective evaluation of the diagnostic accuracy of the physical examination for pulmonary hypertension
Chest
(2019) - et al.
Survival in pulmonary hypertension due to chronic lung disease: influence of low diffusuion capacity of the lungs for carbon monoxide
J Heart Lung Transplant
(2019)
The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis
Respir Med
Right ventricular to left ventricular ratio at CT pulmonary angiogram predicts mortality in interstitial lung disease
Chest
Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idopathic pulmonary fibrosis
Respir Med
Exercise-induced pulmonary hypertension: transplating pathophysiological concepts into clinical practice
Chest
Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
Lancet
Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics
Hum Pathol
Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study
Lancet Respir Med
Sildenafil improves walk distance in idiopathic pulmonary fibrosis
Chest
Sildenafil therapy in secondary pulmonary hypertension: is there benefit in prolonged use?
Vascul Pharmacol
Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies
Chest
Rare lung disease research: National Heart, Lung, and Blood Institute's commitment to partnership and progress
Chest
Gene expression profiling in the lungs of patients with PH associated with PF
Chest
Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review
Eur Respir J
Pulmonary hypertension due to interstitial lung disease
Curr Opin Pulm Med
United Therapeutics announces INCREASE study of Tyvaso® meets primary and all secondary endpoints
Pulmonary hypertension in chronic lung disease and hypoxia
Eur Respir J
Primary Pulmonary Hypertension: Report on a WHO Meeting
Serial development of pulmonary hypertension in patients with IPF
Respiration
Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant
Eur Respir J
Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias
PLoS One
Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups
Pulm Circ
Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia
Eur Respir J
A haemodynamic study of pulmonary hypertension in chronic hypersensitivity pneumonitis
Eur Respir J
Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertension
Respirology
Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis
Eur Respir J
Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis
Respiration
Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration
J Clin Invest
Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots
Am J Respir Crit Care Med
Cited by (47)
Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management
2023, The Lancet Respiratory MedicineRecent Advances and Future Prospects of Treatment of Pulmonary Hypertension
2023, Current Problems in Cardiology